Rigel(US:RIGL)2026-03-03 21:06Revenue and Sales Performance - Total revenues for 2025 were $294.3 million, an increase of 64% compared to $179.3 million in 2024, driven by higher product sales and collaboration revenues [500]. - Net product sales of TAVALISSE reached $158.8 million in 2025, a 52% increase from $104.8 million in 2024, attributed to increased quantities sold and higher prices [502]. - REZLIDHIA net product sales were $31.0 million in 2025, up 35% from $23.0 million in 2024, primarily due to increased sales volume [502]. - GAVRETO generated $42.1 million in net product sales in 2025, compared to $17.1 million in 2024, following its commercialization in June 2024 [504]. - The company recognized $62.0 million in contract revenues from collaborations in 2025, a 80% increase from $34.4 million in 2024, largely due to non-cash revenue from collaboration with Lilly [504]. Research and Development - Research and development expenses increased to $33.3 million in 2025, up from $23.4 million in 2024, mainly due to higher clinical trial costs [510]. - Total research and development expenses for 2025 were $33.3 million, an increase from $23.4 million in 2024, with development costs rising to $29.9 million from $20.1 million [517]. - The company is advancing its dual IRAK1/4 inhibitor program in a Phase 1b study, focusing on patients with lower-risk MDS [494]. Operating Expenses - Selling, general and administrative expenses increased to $115.9 million in 2025 from $113.1 million in 2024, primarily due to increased personnel-related costs of $3.8 million [519]. - Cost of product sales for 2025 was $19.6 million, a slight increase from $18.6 million in 2024, influenced by higher royalties and amortization expenses [507]. Cash Flow and Financial Position - As of December 31, 2025, the company had approximately $155.0 million in cash, cash equivalents, and short-term investments, up from $77.3 million in 2024 [526]. - Net cash provided by operating activities in 2025 was $75.7 million, compared to $31.5 million in 2024 [527]. - The company reported a deferred income tax benefit of $245.9 million in 2025, primarily due to the release of valuation allowance on deferred tax assets [523]. Future Outlook and Funding - The company expects future revenues to be impacted by customer demand, changes in rebate programs, and potential new collaborations [506]. - The company expects to receive approximately $1.1 billion in potential future contingent payments under existing collaboration agreements, assuming all potential product candidates achieve every payment-triggering milestone [531]. - Future funding requirements will depend on various factors, including commercialization costs, clinical trial progress, and ability to generate expected revenue [535]. - The company may consider raising additional funds through public or private offerings, which could lead to shareholder dilution [534]. Debt and Obligations - The outstanding principal balance of term loans as of December 31, 2025, was $52.5 million, down from $60.0 million [533]. - As of December 31, 2025, the outstanding principal amount of the term loan was $52.5 million, with $30.0 million due within 12 months [543]. - The company has a contractual obligation related to an agreement potentially subject to cancellation fees amounting to approximately $21.5 million, with $7.3 million due in 2026 and $9.7 million due in 2027 and 2028 [538]. - The company released a $40.0 million remaining cost share liability in the second quarter of 2025 after opting not to co-fund future global development costs under the Lilly Agreement [539]. - The company has a lease agreement with Healthpeak that will expire in July 2027, with a contractual commitment of $1.2 million as of December 31, 2025, of which $0.7 million is payable within 12 months [544]. Market Risks and Investment Policy - Interest on the outstanding loan from MidCap is subject to changes in the Secured Overnight Financing Rate (SOFR), which may materially affect future interest payment obligations [547]. - The company is exposed to market risks, primarily interest rate sensitivities related to its investments and borrowings, with minimal credit risk due to high-grade securities [546]. - The company’s investment policy focuses on liquidity and capital preservation, avoiding speculative investments and derivative financial instruments [546]. - The maximum cancellation fees for contract manufacturing agreements are generally equal to the full price of the work order, depending on the timing of written notice [538]. - The company has not incurred any cancellation fees under its agreements with contract manufacturers as of December 31, 2025 [538].